<DOC>
	<DOC>NCT01370629</DOC>
	<brief_summary>This non-interventional prospective study is a post-authorization safety study (PASS) of vernakalant conducted to collect information about normal conditions of use and appropriate dosing, and to quantify possible medically significant risks associated with the use of vernakalant in real-world clinical practice.</brief_summary>
	<brief_title>Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>To be treated with intravenous vernakalant, independently of this study Participant and/or legal guardians willing to provide informed consent and/or informed assent according to local regulations Enrollment in an investigational drug or device clinical trial in the 30 days prior to study enrolment. Participation in another noninterventional drug or device study or registry is permitted.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>cardioversion</keyword>
</DOC>